Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) Overview 6 Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS).Therapeutics Development 6 Therapeutics Development 7 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Products under Development by Stage of Development 7 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Products under Development by Therapy Area 8 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Products under Development by Indication 9 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Products under Development by Companies 12 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Companies Involved in Therapeutics Development 21 Addex Therapeutics Ltd 21 G&E Herbal Biotechnology Co., Ltd. 22 GlaxoSmithKline Plc 23 Inflamalps SA 24 Polaris Pharmaceuticals, Inc. 25 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Drug Profiles 26 Drugs to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 GSK-2862277 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 SRT-100 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 TNF-PEG 20 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Dormant Projects 33 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Discontinued Products 36 Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or CD120a or TNFRSF1A) - Featured News & Press Releases 37 Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 37 Jan 02, 2012: SR-T100 gel phase III clinical trial was selected as the Center for Drug Evaluation 100 annual cases of major indicators of new drugs 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39

List of Tables Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Addex Therapeutics Ltd, H1 2016 21 Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016 22 Pipeline by GlaxoSmithKline Plc, H1 2016 23 Pipeline by Inflamalps SA, H1 2016 24 Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 25 Dormant Projects, H1 2016 33 Dormant Projects (Contd..1), H1 2016 34 Dormant Projects (Contd..2), H1 2016 35 Discontinued Products, H1 2016 36 List of Figures Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Mechanism of Actions, H1 2016 15 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Routes of Administration, H1 2016 17 Number of Products by Stage and Routes of Administration, H1 2016 17 Number of Products by Molecule Types, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 19

Addex Therapeutics Ltd G&E Herbal Biotechnology Co., Ltd. GlaxoSmithKline Plc Inflamalps SA Polaris Pharmaceuticals, Inc.